Sandra Aung

SVP, Chief Clinical Development Officer

As Senior Vice President, Chief Clinical Development Officer, Dr. Aung is responsible for overseeing KEYNOTE-695, the Company's Phase 2b trial evaluating intratumoral delivery of its interleukin-12 (IL-12) based immunotherapy, TAVO™ (tavokinogene telseplasmid), in combination with intravenous KEYTRUDA® (pembrolizumab) in patients with unresecta...

Roles at OncoSec

  • SVP, Chief Clinical Development Officer

    October 12, 2020 - present

My work style

How I prefer to work

Qualities I value in my colleagues

Sign up to see more about the team at OncoSec

My pet peeves

My communication style

Org chart

Direct reports

No reports


No teams

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.